{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:44:56Z","timestamp":1791866696612,"version":"4.3.4"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genes Immun"],"DOI":"10.1038\/s41435-026-00409-y","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:47:43Z","timestamp":1785520063000},"page":"516-529","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A transcriptional signature of resting mast cells is associated with improved disease outcome in HR+HER2- breast cancer"],"prefix":"10.1038","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2284-7424","authenticated-orcid":false,"given":"Alexander","family":"Kirchmair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Galassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esmeralda","family":"Garc\u00eda-Torralba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0636-7351","authenticated-orcid":false,"given":"Zlatko","family":"Trajanoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aitziber","family":"Buqu\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2257-8500","authenticated-orcid":false,"given":"Lorenzo","family":"Galluzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"409_CR1","first-page":"287","volume":"5","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Ji Y, Liu S, Li J, Wu J, Jin Q, et al. Global burden of female breast cancer: new estimates in 2022, temporal trend and future projections up to 2050 based on the latest release from GLOBOCAN. J Natl Cancer Cent. 2025;5:287\u201396.","journal-title":"J Natl Cancer Cent"},{"key":"409_CR2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","volume":"5","author":"N Harbeck","year":"2019","unstructured":"Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nat Rev Dis Prim. 2019;5:66.","journal-title":"Nat Rev Dis Prim"},{"key":"409_CR3","first-page":"477","volume":"74","author":"AN Giaquinto","year":"2024","unstructured":"Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, et al. Breast cancer statistics 2024. CA Cancer J Clin. 2024;74:477\u201395.","journal-title":"CA Cancer J Clin"},{"key":"409_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387:217\u201326.","journal-title":"N Engl J Med"},{"key":"409_CR5","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1056\/NEJMoa2508668","volume":"394","author":"SM Tolaney","year":"2026","unstructured":"Tolaney SM, Jiang Z, Zhang Q, Barroso-Sousa R, Park YH, Rimawi MF, et al. Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer. N Engl J Med. 2026;394:551\u201362.","journal-title":"N Engl J Med"},{"key":"409_CR6","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMoa2114663","volume":"386","author":"GN Hortobagyi","year":"2022","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386:942\u201350.","journal-title":"N Engl J Med"},{"key":"409_CR7","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384:2394\u2013405.","journal-title":"N Engl J Med"},{"key":"409_CR8","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41568-024-00705-7","volume":"24","author":"AM Holder","year":"2024","unstructured":"Holder AM, Dedeilia A, Sierra-Davidson K, Cohen S, Liu D, Parikh A, et al. Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours. Nat Rev Cancer. 2024;24:498\u2013512.","journal-title":"Nat Rev Cancer"},{"key":"409_CR9","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810\u201321.","journal-title":"N Engl J Med"},{"key":"409_CR10","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.path.2025.07.003","volume":"18","author":"SK Maley","year":"2025","unstructured":"Maley SK, Khiroya R, Provenzano E, Salgado R. Tumor infiltrating lymphocytes in breast cancer: why is it useful to know? Surg Pathol Clin. 2025;18:725\u201333.","journal-title":"Surg Pathol Clin"},{"key":"409_CR11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","volume":"19","author":"C Denkert","year":"2018","unstructured":"Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19:40\u201350.","journal-title":"Lancet Oncol"},{"key":"409_CR12","doi-asserted-by":"crossref","unstructured":"Garcia-Torralba E, Loi S, Salgado R, Galluzzi L, Buque A. The immunology of human breast cancer. Nat Rev Immunol. 2026: In press.","DOI":"10.1038\/s41577-026-01307-0"},{"key":"409_CR13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40425-018-0344-8","volume":"6","author":"C Morrison","year":"2018","unstructured":"Morrison C, Pabla S, Conroy JM, Nesline MK, Glenn ST, Dressman D, et al. Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden. J Immunother Cancer. 2018;6:32.","journal-title":"J Immunother Cancer"},{"key":"409_CR14","first-page":"187","volume":"74","author":"G Kroemer","year":"2024","unstructured":"Kroemer G, Chan TA, Eggermont AMM, Galluzzi L. Immunosurveillance in clinical cancer management. CA Cancer J Clin. 2024;74:187\u2013202.","journal-title":"CA Cancer J Clin"},{"key":"409_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Cancer Genome Atlas N","year":"2012","unstructured":"Cancer Genome Atlas NComprehensive molecular portraits of human breast tumours. Nature. 2012;490:61\u201370.","journal-title":"Nature"},{"key":"409_CR16","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346\u201352.","journal-title":"Nature"},{"key":"409_CR17","doi-asserted-by":"publisher","first-page":"10869","DOI":"10.1073\/pnas.191367098","volume":"98","author":"T Sorlie","year":"2001","unstructured":"Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869\u201374.","journal-title":"Proc Natl Acad Sci USA"},{"key":"409_CR18","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1093\/nar\/gkv1507","volume":"44","author":"A Colaprico","year":"2016","unstructured":"Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, et al. TCGAbiolinks: an R\/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44:e71.","journal-title":"Nucleic Acids Res"},{"key":"409_CR19","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","volume":"173","author":"J Liu","year":"2018","unstructured":"Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, et al. An Integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018;173:400\u2013416.e411.","journal-title":"Cell"},{"key":"409_CR20","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41586-019-1007-8","volume":"567","author":"OM Rueda","year":"2019","unstructured":"Rueda OM, Sammut SJ, Seoane JA, Chin SF, Caswell-Jin JL, Callari M, et al. Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. Nature. 2019;567:399\u2013404.","journal-title":"Nature"},{"key":"409_CR21","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.","journal-title":"Nucleic Acids Res"},{"key":"409_CR22","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453\u20137.","journal-title":"Nat Methods"},{"key":"409_CR23","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsd\u00f3ttir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417\u201325.","journal-title":"Cell Syst"},{"key":"409_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Mart\u00ednez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.","journal-title":"Nat Commun"},{"key":"409_CR25","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/978-1-0716-0327-7_16","volume":"2120","author":"G Sturm","year":"2020","unstructured":"Sturm G, Finotello F, List M. Immunedeconv: an R package for unified access to computational methods for estimating immune cell fractions from bulk RNA-sequencing data. Methods Mol Biol. 2020;2120:223\u201332.","journal-title":"Methods Mol Biol"},{"key":"409_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-83913-7","volume":"11","author":"KE Craven","year":"2021","unstructured":"Craven KE, G\u00f6kmen-Polar Y, Badve SS. CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer. Sci Rep. 2021;11:4691.","journal-title":"Sci Rep"},{"key":"409_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/nargab\/lqaf217","volume":"8","author":"A Chen","year":"2026","unstructured":"Chen A, Kroehling L, Ennis CS, Denis GV, Monti S. A highly resolved integrated single-cell atlas of human breast cancers. NAR Genom Bioinform. 2026;8:lqaf217.","journal-title":"NAR Genom Bioinform"},{"key":"409_CR28","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM 3rd, et al. Comprehensive integration of single-cell data. Cell. 2019;177:1888\u20131902.e1821.","journal-title":"Cell"},{"key":"409_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"409_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30755-0","volume":"13","author":"D Dimitrov","year":"2022","unstructured":"Dimitrov D, T\u00fcrei D, Garrido-Rodriguez M, Burmedi PL, Nagai JS, Boys C, et al. Comparison of methods and resources for cell-cell communication inference from single-cell RNA-Seq data. Nat Commun. 2022;13:3224.","journal-title":"Nat Commun"},{"key":"409_CR31","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/nmeth.4463","volume":"14","author":"S Aibar","year":"2017","unstructured":"Aibar S, Gonz\u00e1lez-Blas CB, Moerman T, Huynh-Thu VA, Imrichova H, Hulselmans G, et al. SCENIC: single-cell regulatory network inference and clustering. Nat Methods. 2017;14:1083\u20136.","journal-title":"Nat Methods"},{"key":"409_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0638-6","volume":"11","author":"F Finotello","year":"2019","unstructured":"Finotello F, Mayer C, Plattner C, Laschober G, Rieder D, Hackl H, et al. Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Med. 2019;11:34.","journal-title":"Genome Med"},{"key":"409_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50618-0","volume":"15","author":"BS White","year":"2024","unstructured":"White BS, de Reynies A, Newman AM, Waterfall JJ, Lamb A, Petitprez F, et al. Community assessment of methods to deconvolve cellular composition from bulk gene expression. Nat Commun. 2024;15:7362.","journal-title":"Nat Commun"},{"key":"409_CR34","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1146\/annurev-immunol-101220-015603","volume":"40","author":"SM Downs-Canner","year":"2022","unstructured":"Downs-Canner SM, Meier J, Vincent BG, Serody JS. B Cell Function in the Tumor Microenvironment. Annu Rev Immunol. 2022;40:169\u201393.","journal-title":"Annu Rev Immunol"},{"key":"409_CR35","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s12307-012-0122-y","volume":"6","author":"C Tanchot","year":"2013","unstructured":"Tanchot C, Terme M, Pere H, Tran T, Benhamouda N, Strioga M, et al. Tumor-infiltrating regulatory T cells: phenotype, role, mechanism of expansion in situ and clinical significance. Cancer Microenviron. 2013;6:147\u201357.","journal-title":"Cancer Microenviron"},{"key":"409_CR36","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1146\/annurev-immunol-082223-044122","volume":"43","author":"L Rausch","year":"2025","unstructured":"Rausch L, Kallies A. Molecular mechanisms governing CD8 T cell differentiation and checkpoint inhibitor response in cancer. Annu Rev Immunol. 2025;43:515\u201343.","journal-title":"Annu Rev Immunol"},{"key":"409_CR37","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20241417","volume":"222","author":"H Venkatesh","year":"2025","unstructured":"Venkatesh H, Fong L. CD4+ T cell dysfunction in cancer. J Exp Med. 2025;222:e20241417.","journal-title":"J Exp Med"},{"key":"409_CR38","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","volume":"21","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. 2022;21:799\u2013820.","journal-title":"Nat Rev Drug Discov"},{"key":"409_CR39","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/s41573-025-01210-8","volume":"24","author":"JW Kwak","year":"2025","unstructured":"Kwak JW, Houghton AM. Targeting neutrophils for cancer therapy. Nat Rev Drug Discov. 2025;24:666\u201384.","journal-title":"Nat Rev Drug Discov"},{"key":"409_CR40","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1158\/0008-5472.CAN-21-3424","volume":"82","author":"MT Majorini","year":"2022","unstructured":"Majorini MT, Colombo MP, Lecis D. Few, but efficient: the role of mast cells in breast cancer and other solid tumors. Cancer Res. 2022;82:1439\u201347.","journal-title":"Cancer Res"},{"key":"409_CR41","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/jnci\/djac157","volume":"114","author":"S Oesterreich","year":"2022","unstructured":"Oesterreich S, Nasrazadani A, Zou J, Carleton N, Onger T, Wright MD, et al. Clinicopathological features and outcomes comparing patients with invasive ductal and lobular breast cancer. J Natl Cancer Inst. 2022;114:1511\u201322.","journal-title":"J Natl Cancer Inst"},{"key":"409_CR42","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1146\/annurev-immunol-090222-102834","volume":"42","author":"W Song","year":"2024","unstructured":"Song W, Craft J. T follicular helper cell heterogeneity. Annu Rev Immunol. 2024;42:127\u201352.","journal-title":"Annu Rev Immunol"},{"key":"409_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01672-z","volume":"21","author":"L Tong","year":"2022","unstructured":"Tong L, Jim\u00e9nez-Cortegana C, Tay AHM, Wickstr\u00f6m S, Galluzzi L, Lundqvist A. NK cells and solid tumors: therapeutic potential and persisting obstacles. Mol Cancer. 2022;21:206.","journal-title":"Mol Cancer"},{"key":"409_CR44","doi-asserted-by":"publisher","first-page":"e1655964","DOI":"10.1080\/2162402X.2019.1655964","volume":"8","author":"ME Rodriguez-Ruiz","year":"2019","unstructured":"Rodriguez-Ruiz ME, Buqu\u00e9 A, Hensler M, Chen J, Bloy N, Petroni G. Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients. Oncoimmunology. 2019;8:e1655964.","journal-title":"Oncoimmunology"},{"key":"409_CR45","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","volume":"19","author":"DJ Propper","year":"2022","unstructured":"Propper DJ, Balkwill FR. Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol. 2022;19:237\u201353.","journal-title":"Nat Rev Clin Oncol"},{"key":"409_CR46","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/0092-8674(90)90298-S","volume":"63","author":"NG Copeland","year":"1990","unstructured":"Copeland NG, Gilbert DJ, Cho BC, Donovan PJ, Jenkins NA, Cosman D, et al. Mast cell growth factor maps near the steel locus on mouse chromosome 10 and is deleted in a number of steel alleles. Cell. 1990;63:175\u201383.","journal-title":"Cell"},{"key":"409_CR47","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/0092-8674(90)90303-V","volume":"63","author":"E Huang","year":"1990","unstructured":"Huang E, Nocka K, Beier DR, Chu TY, Buck J, Lahm HW, et al. The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell. 1990;63:225\u201333.","journal-title":"Cell"},{"key":"409_CR48","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1002\/j.1460-2075.1990.tb07528.x","volume":"9","author":"K Nocka","year":"1990","unstructured":"Nocka K, Buck J, Levi E, Besmer P. Candidate ligand for the c-kit transmembrane kinase receptor: KL, a fibroblast derived growth factor stimulates mast cells and erythroid progenitors. EMBO J. 1990;9:3287\u201394.","journal-title":"EMBO J"},{"key":"409_CR49","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/0092-8674(90)90300-4","volume":"63","author":"KM Zsebo","year":"1990","unstructured":"Zsebo KM, Wypych J, McNiece IK, Lu HS, Smith KA, Karkare SB, et al. Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver-conditioned medium. Cell. 1990;63:195\u2013201.","journal-title":"Cell"},{"key":"409_CR50","doi-asserted-by":"publisher","first-page":"6382","DOI":"10.1073\/pnas.88.14.6382","volume":"88","author":"M Tsai","year":"1991","unstructured":"Tsai M, Takeishi T, Thompson H, Langley KE, Zsebo KM, Metcalfe DD, et al. Induction of mast cell proliferation, maturation, and heparin synthesis by the rat c-kit ligand, stem cell factor. Proc Natl Acad Sci USA. 1991;88:6382\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"409_CR51","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.3390\/biom12111674","volume":"12","author":"J Nulali","year":"2022","unstructured":"Nulali J, Zhan M, Zhang K, Tu P, Liu Y, Song H. Osteoglycin: an ECM factor regulating fibrosis and tumorigenesis. Biomolecules. 2022;12:1674.","journal-title":"Biomolecules"},{"key":"409_CR52","doi-asserted-by":"publisher","first-page":"R65","DOI":"10.1186\/bcr587","volume":"5","author":"MJ N\u00fa\u00f1ez-Villar","year":"2003","unstructured":"N\u00fa\u00f1ez-Villar MJ, Mart\u00ednez-Arribas F, Poll\u00e1n M, Lucas AR, S\u00e1nchez J, Tejerina A, et al. Elevated mammaglobin (h-MAM) expression in breast cancer is associated with clinical and biological features defining a less aggressive tumour phenotype. Breast Cancer Res. 2003;5:R65\u201370.","journal-title":"Breast Cancer Res"},{"key":"409_CR53","doi-asserted-by":"publisher","first-page":"33253","DOI":"10.18632\/oncotarget.5291","volume":"6","author":"D Cheishvili","year":"2015","unstructured":"Cheishvili D, Stefanska B, Yi C, Li CC, Yu P, Arakelian A, et al. A common promoter hypomethylation signature in invasive breast, liver and prostate cancer cell lines reveals novel targets involved in cancer invasiveness. Oncotarget. 2015;6:33253\u201368.","journal-title":"Oncotarget"},{"key":"409_CR54","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.ajpath.2011.11.025","volume":"180","author":"D Su","year":"2012","unstructured":"Su D, Fu X, Fan S, Wu X, Wang XX, Fu L, et al. Role of ERRF, a novel ER-related nuclear factor, in the growth control of ER-positive human breast cancer cells. Am J Pathol. 2012;180:1189\u2013201.","journal-title":"Am J Pathol"},{"key":"409_CR55","first-page":"235","volume":"18","author":"JP Mu\u00f1oz","year":"2025","unstructured":"Mu\u00f1oz JP, Lampe-Huenul N. Predictive value of STC2 gene expression in chemotherapy response in breast cancer. Pharm (Basel). 2025;18:235.","journal-title":"Pharm (Basel)"},{"key":"409_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58552-5","volume":"16","author":"Y Yan","year":"2025","unstructured":"Yan Y, Yu J, Wang W, Xu Y, Tison K, Xiao R, et al. Palmitoylation prevents B7-H4 lysosomal degradation sustaining tumor immune evasion. Nat Commun. 2025;16:4254.","journal-title":"Nat Commun"},{"key":"409_CR57","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1093\/nar\/gkh626","volume":"32","author":"A Mitchell","year":"2004","unstructured":"Mitchell A, Dass CR, Sun LQ, Khachigian LM. Inhibition of human breast carcinoma proliferation, migration, chemoinvasion and solid tumour growth by DNAzymes targeting the zinc finger transcription factor EGR-1. Nucleic Acids Res. 2004;32:3065\u20139.","journal-title":"Nucleic Acids Res"},{"key":"409_CR58","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1038\/sj.onc.1204377","volume":"20","author":"JH Ludes-Meyers","year":"2001","unstructured":"Ludes-Meyers JH, Liu Y, Mu\u00f1oz-Medellin D, Hilsenbeck SG, Brown PH. AP-1 blockade inhibits the growth of normal and malignant breast cells. Oncogene. 2001;20:2771\u201380.","journal-title":"Oncogene"},{"key":"409_CR59","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/ijc.2910600215","volume":"60","author":"P Cassoni","year":"1995","unstructured":"Cassoni P, Sapino A, Haagensen DE, Naldoni C, Bussolati G. Mitogenic effect of the 15-kDa gross cystic disease fluid protein (GCDFP-15) on breast-cancer cell lines and on immortal mammary cells. Int J Cancer. 1995;60:216\u201320.","journal-title":"Int J Cancer"},{"key":"409_CR60","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1210\/en.2009-0066","volume":"150","author":"N Amiry","year":"2009","unstructured":"Amiry N, Kong X, Muniraj N, Kannan N, Grandison PM, Lin J, et al. Trefoil factor-1 (TFF1) enhances oncogenicity of mammary carcinoma cells. Endocrinology. 2009;150:4473\u201383.","journal-title":"Endocrinology"},{"key":"409_CR61","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1172\/JCI64410","volume":"123","author":"CC Wolford","year":"2013","unstructured":"Wolford CC, McConoughey SJ, Jalgaonkar SP, Leon M, Merchant AS, Dominick JL, et al. Transcription factor ATF3 links host adaptive response to breast cancer metastasis. J Clin Invest. 2013;123:2893\u2013906.","journal-title":"J Clin Invest"},{"key":"409_CR62","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00262-011-1135-y","volume":"61","author":"J Lin","year":"2012","unstructured":"Lin J, Huo R, Wang L, Zhou Z, Sun Y, Shen B, et al. A novel anti-Cyr61 antibody inhibits breast cancer growth and metastasis in vivo. Cancer Immunol Immunother. 2012;61:677\u201387.","journal-title":"Cancer Immunol Immunother"},{"key":"409_CR63","first-page":"97","volume":"13","author":"AJ Oates","year":"1996","unstructured":"Oates AJ, Barraclough R, Rudland PS. The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene. 1996;13:97\u2013104.","journal-title":"Oncogene"},{"key":"409_CR64","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/nature08021","volume":"459","author":"PD Bos","year":"2009","unstructured":"Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, et al. Genes that mediate breast cancer metastasis to the brain. Nature. 2009;459:1005\u20139.","journal-title":"Nature"},{"key":"409_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115775","volume":"144","author":"C Spadazzi","year":"2021","unstructured":"Spadazzi C, Mercatali L, Esposito M, Wei Y, Liverani C, De Vita A, et al. Trefoil factor-1 upregulation in estrogen-receptor positive breast cancer correlates with an increased risk of bone metastasis. Bone. 2021;144:115775.","journal-title":"Bone"},{"key":"409_CR66","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41568-023-00635-w","volume":"24","author":"TR Mempel","year":"2024","unstructured":"Mempel TR, Lill JK, Altenburger LM. How chemokines organize the tumour microenvironment. Nat Rev Cancer. 2024;24:28\u201350.","journal-title":"Nat Rev Cancer"},{"key":"409_CR67","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41577-024-01026-4","volume":"24","author":"M De Martino","year":"2024","unstructured":"De Martino M, Rathmell JC, Galluzzi L, Vanpouille-Box C. Cancer cell metabolism and antitumour immunity. Nat Rev Immunol. 2024;24:654\u201369.","journal-title":"Nat Rev Immunol"},{"key":"409_CR68","doi-asserted-by":"publisher","first-page":"43091","DOI":"10.1074\/jbc.M111.295865","volume":"286","author":"CC Chen","year":"2011","unstructured":"Chen CC, Hardy DB, Mendelson CR. Progesterone receptor inhibits proliferation of human breast cancer cells via induction of MAPK phosphatase 1 (MKP-1\/DUSP1). J Biol Chem. 2011;286:43091\u2013102.","journal-title":"J Biol Chem"},{"key":"409_CR69","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1007\/s12672-024-01607-8","volume":"15","author":"L Zeng","year":"2024","unstructured":"Zeng L, Zeng J, He J, Li Y, Li C, Lin Z, et al. FCGBP functions as a tumor suppressor gene in head and neck squamous cell carcinoma. Discov Oncol. 2024;15:704.","journal-title":"Discov Oncol"},{"key":"409_CR70","doi-asserted-by":"publisher","first-page":"10213","DOI":"10.2147\/IJGM.S341959","volume":"14","author":"X Wang","year":"2021","unstructured":"Wang X, Xue D, Zhu X, Geng R, Bao X, Chen X, et al. Low expression of PLAT in breast cancer infers poor prognosis and high immune infiltrating level. Int J Gen Med. 2021;14:10213\u201324.","journal-title":"Int J Gen Med"},{"key":"409_CR71","doi-asserted-by":"publisher","first-page":"5858","DOI":"10.1038\/sj.onc.1207774","volume":"23","author":"G Vaidyanathan","year":"2004","unstructured":"Vaidyanathan G, Cismowski MJ, Wang G, Vincent TS, Brown KD, Lanier SM. The Ras-related protein AGS1\/RASD1 suppresses cell growth. Oncogene. 2004;23:5858\u201363.","journal-title":"Oncogene"},{"key":"409_CR72","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10911-020-09448-1","volume":"25","author":"R Canzoneri","year":"2020","unstructured":"Canzoneri R, Naipauer J, Stedile M, Rodriguez Pe\u00f1a A, Lacunza E, Gandini NA, et al. Identification of an AP1-ZFP36 regulatory network associated with breast cancer prognosis. J Mammary Gland Biol Neoplasia. 2020;25:163\u201372.","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"409_CR73","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1084\/jem.20182031","volume":"216","author":"K Tretina","year":"2019","unstructured":"Tretina K, Park ES, Maminska A, MacMicking JD. Interferon-induced guanylate-binding proteins: guardians of host defense in health and disease. J Exp Med. 2019;216:482\u2013500.","journal-title":"J Exp Med"},{"key":"409_CR74","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1038\/s41556-024-01469-w","volume":"26","author":"D Dimitrov","year":"2024","unstructured":"Dimitrov D, Sch\u00e4fer PSL, Farr E, Rodriguez-Mier P, Lobentanzer S, Badia IMP, et al. LIANA+ provides an all-in-one framework for cell-cell communication inference. Nat Cell Biol. 2024;26:1613\u201322.","journal-title":"Nat Cell Biol"},{"key":"409_CR75","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41577-021-00622-y","volume":"22","author":"P Kolkhir","year":"2022","unstructured":"Kolkhir P, Elieh-Ali-Komi D, Metz M, Siebenhaar F, Maurer M. Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases. Nat Rev Immunol. 2022;22:294\u2013308.","journal-title":"Nat Rev Immunol"},{"key":"409_CR76","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1200\/PO.19.00350","volume":"4","author":"T O\u2019Meara","year":"2020","unstructured":"O\u2019Meara T, Marczyk M, Qing T, Yaghoobi V, Blenman K, Cole K. Immunological differences between immune-rich estrogen receptor\u2013positive and immune-rich triple-negative breast cancers. JCO Precision Oncol. 2020;4:767\u201379.","journal-title":"JCO Precision Oncol"},{"key":"409_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13329-5","volume":"10","author":"X Tekpli","year":"2019","unstructured":"Tekpli X, Lien T, R\u00f8ssevold AH, Nebdal D, Borgen E, Ohnstad HO, et al. An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment. Nat Commun. 2019;10:5499.","journal-title":"Nat Commun"},{"key":"409_CR78","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.it.2016.06.002","volume":"37","author":"AT Ting","year":"2016","unstructured":"Ting AT, Bertrand MJM. More to Life than NF-kappaB in TNFR1 Signaling. Trends Immunol. 2016;37:535\u201345.","journal-title":"Trends Immunol"},{"key":"409_CR79","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s10555-024-10206-6","volume":"43","author":"O Ababneh","year":"2024","unstructured":"Ababneh O, Nishizaki D, Kato S, Kurzrock R. Tumor necrosis factor superfamily signaling: life and death in cancer. Cancer Metastasis Rev. 2024;43:1137\u201363.","journal-title":"Cancer Metastasis Rev"},{"key":"409_CR80","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41568-024-00781-9","volume":"25","author":"A Suvac","year":"2025","unstructured":"Suvac A, Ashton J, Bristow RG. Tumour hypoxia in driving genomic instability and tumour evolution. Nat Rev Cancer. 2025;25:167\u201388.","journal-title":"Nat Rev Cancer"},{"key":"409_CR81","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adp2442","volume":"10","author":"S Artham","year":"2024","unstructured":"Artham S, Juras PK, Goyal A, Chakraborty P, Byemerwa J, Liu S, et al. Estrogen signaling suppresses tumor-associated tissue eosinophilia to promote breast tumor growth. Sci Adv. 2024;10:eadp2442.","journal-title":"Sci Adv"},{"key":"409_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2023.152151","volume":"65","author":"O Okcu","year":"2023","unstructured":"Okcu O, \u00d6zt\u00fcrk \u00c7, \u015een B, Ayazo\u011flu MS, G\u00fcvendi GF, \u00d6zt\u00fcrk SD, et al. The prognostic significance of non-lymphoid immune cells of the tumor microenvironment, including neutrophils, eosinophils, and mast cells in breast carcinomas. Ann Diagn Pathol. 2023;65:152151.","journal-title":"Ann Diagn Pathol"},{"key":"409_CR83","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.surg.2020.07.052","volume":"169","author":"K Chouliaras","year":"2021","unstructured":"Chouliaras K, Tokumaru Y, Asaoka M, Oshi M, Attwood KM, Yoshida K, et al. Prevalence and clinical relevance of tumor-associated tissue eosinophilia (TATE) in breast cancer. Surgery. 2021;169:1234\u20139.","journal-title":"Surgery"},{"key":"409_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113787","volume":"155","author":"WQ Wang","year":"2022","unstructured":"Wang WQ, Zhang L, Yang F, Zhou HH, Zhang W, Zou Y, et al. Patterns of immune infiltration and survival in endocrine therapy-treated ER-positive breast cancer: A computational study of 1900 patients. Biomed Pharmacother. 2022;155:113787.","journal-title":"Biomed Pharmacother"},{"key":"409_CR85","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/biotech15010007","volume":"15","author":"J Sun","year":"2026","unstructured":"Sun J, Xiao Y, Xie L, Qin D, Zou Y, Liu Y, et al. Multi-scale transcriptomics redefining the tumor immune microenvironment. BioTech (Basel). 2026;15:7.","journal-title":"BioTech (Basel)"},{"key":"409_CR86","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-023-03123-4","volume":"24","author":"SK Maden","year":"2023","unstructured":"Maden SK, Kwon SH, Huuki-Myers LA, Collado-Torres L, Hicks SC, Maynard KR. Challenges and opportunities to computationally deconvolve heterogeneous tissue with varying cell sizes using single-cell RNA-sequencing datasets. Genome Biol. 2023;24:288.","journal-title":"Genome Biol"},{"key":"409_CR87","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41568-025-00886-9","volume":"26","author":"Y Dai","year":"2026","unstructured":"Dai Y, Guo S, Pan Y, Castignani C, Montierth MD, Van Loo P, et al. A guide to transcriptomic deconvolution in cancer. Nat Rev Cancer. 2026;26:84\u2013103.","journal-title":"Nat Rev Cancer"},{"key":"409_CR88","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.4161\/onci.22009","volume":"1","author":"L Senovilla","year":"2012","unstructured":"Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, et al. Trial watch: prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology. 2012;1:1323\u201343.","journal-title":"Oncoimmunology"},{"key":"409_CR89","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jclinepi.2023.03.025","volume":"158","author":"Y Jin","year":"2023","unstructured":"Jin Y, Kattan MW. Practical guide to the typical analysis of prognostic factors and biomarkers without the use of P-values. J Clin Epidemiol. 2023;158:179\u201384.","journal-title":"J Clin Epidemiol"},{"key":"409_CR90","doi-asserted-by":"publisher","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","volume":"158","author":"JA Hayden","year":"2013","unstructured":"Hayden JA, van der Windt DA, Cartwright JL, Cote P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013;158:280\u20136.","journal-title":"Ann Intern Med"},{"key":"409_CR91","doi-asserted-by":"publisher","first-page":"5630","DOI":"10.1158\/0008-5472.CAN-09-1055","volume":"69","author":"DA Solomon","year":"2009","unstructured":"Solomon DA, Kim JS, Ressom HW, Sibenaller Z, Ryken T, Jean W, et al. Sample type bias in the analysis of cancer genomes. Cancer Res. 2009;69:5630\u20133.","journal-title":"Cancer Res"},{"key":"409_CR92","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s10549-007-9546-3","volume":"107","author":"AB Rajput","year":"2008","unstructured":"Rajput AB, Turbin DA, Cheang MC, Voduc DK, Leung S, Gelmon KA, et al. Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. Breast Cancer Res Treat. 2008;107:249\u201357.","journal-title":"Breast Cancer Res Treat"}],"container-title":["Genes & Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41435-026-00409-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41435-026-00409-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41435-026-00409-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:50:40Z","timestamp":1791863440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41435-026-00409-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":92,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["409"],"URL":"https:\/\/doi.org\/10.1038\/s41435-026-00409-y","relation":{},"ISSN":["1476-5470"],"issn-type":[{"value":"1476-5470","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"8 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LG is\/has been holding research contracts with Lytix Biopharma, Promontory and Onxeo, has received consulting\/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, Onxeo, The Longevity Labs, Inzen, Imvax, Sotio, Promontory, Noxopharm, EduCom, and the Luke Heller TECPR2 Foundation, and holds Promontory stock options. All other authors have no conflicts to declare.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study exclusively analyzed de-identified, publicly available datasets from public repositories. No new human participants or animals were involved, and no identifiable personal information was accessed. Ethical approval and informed consent were obtained by the original studies, where applicable. Accordingly, additional institutional review board approval and informed consent were not required for this secondary analysis. All analytical methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Every co-author has reviewed the final version of the manuscript and approved it for publication.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Ethics"}}]}}